Biocon Biologics, a subsidiary of Biocon, reported on Thursday, 10 April, that the US Food and Drug Administration (FDA) had approved its antibody Jobevne.
The company’s exchange filing states that Jobevne is a humanized monoclonal antibody used to treat various cancers.
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that works by binding to VEGF and blocking its interaction with receptors, thereby stopping the formation of new blood vessels (angiogenesis). This limits the tumour’s blood supply, helping to fight cancer.
With this approval, Biocon Biologics has strengthened its oncology offerings in the US, adding to its existing products Ogivri and Fulphila.
In 2023, bevacizumab generated approximately $2 billion in US sales. Biocon now competes in this space alongside Amgen, Amneal, Celltrion, and Pfizer.
The company also sells bevacizumab under the brand name Abevmy in Europe and Canada, where it received approval in 2021.
Shreehas Tambe, CEO & Managing Director of Biocon Biologics Ltd., said: “The USFDA approval is a significant milestone—our seventh biosimilar approved in the US and a strong addition to our robust oncology portfolio. It underscores the depth of our scientific expertise and commitment to expanding access to high-quality, affordable biologics.
Ready to invest like a pro? Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists and insightful market analysis and much more!
